Following the closing of the Capsugel acquisition, Lonza will further strengthen its position as a trusted supplier to the pharmaceutical, biotech and specialty ingredients markets
Image copyright Lonza 2017
Lonza has received all regulatory approvals for the proposed acquisition of Capsugel S.A. by Lonza.
With all final regulatory approvals in place, Lonza can now complete the transaction, which is expected to close in the next days subject to the satisfaction of customary closing conditions.
Lonza harnesses science and technology to create products that support safer and healthier living and enhance the overall quality of life.
An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
In addition to producing drinking-water sanitisers, nutraceuticals, anti dandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and research and development facilities and around 10000 full time employees worldwide.